Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround

Group 1 - Terns Pharmaceuticals, Inc. (TERN) has experienced a significant downtrend, with a stock decline of 39.8% over the past four weeks, indicating excessive selling pressure [1] - The stock is currently in oversold territory, as evidenced by an RSI reading of 21.87, suggesting a potential reversal in trend [5] - Wall Street analysts have shown strong agreement in raising earnings estimates for TERN, with a 6.5% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [7] Group 2 - TERN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8]